What’s Next for Unicycive Therapeutics, Inc. Shareholders After 39.1% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline
Complaint alleges Unicycive Therapeutics, Inc. misled investors between December 29, 2025 and June 29, 2026; investors may seek lead plaintiff...
Read moreDetails